Immunotherapy associated Sweet syndrome in a patient with metastatic melanoma: A case report
Abstract Immunotherapy agents are now widely used in the treatment of metastatic melanoma. Immune‐related adverse events (irAEs) may occur, including cutaneous pathologies in 50% of patients. We report a case of Sweet syndrome (SS) in a patient who was prescribed ipilimumab and nivolumab for metasta...
Saved in:
Main Authors: | Rory Barry (Author), Gregg Murray (Author), Sally McGrath (Author), Clive Kilgallen (Author), Karen Eustace (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
[Translated article] Cryosurgery as an Adjuvant to Immunotherapy in Metastatic Melanoma
by: L.P. González-Cardona, et al.
Published: (2023) -
Treatment of BRAF-Mutated Metastatic Melanoma: Immunotherapy or Target Therapy?
by: Ana Sofia Rodrigues, et al.
Published: (2021) -
Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
by: Gérald E. Piérard, et al.
Published: (2012) -
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
by: Lærke K. Tolstrup, et al.
Published: (2019) -
Chronic granulomatous reaction in patients receiving vaccine immunotherapy for metastatic melanoma
by: Alexander B. Aria, BS, et al.
Published: (2018)